Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2018 / N 3

Возможности лечения тревожных расстройств с использованием препарата Тенотен
С.Н. Иллариошкин, М.А. Домашенко, М.В. Ершова, К.К. Хачева
Отзыв из печати статьи Иллариошкина С.Н., Домашенко М.А., Ершовой М.В., Хачевой К.К. "Возможности лечения тревожных расстройств с использованием препарата Тенотен". Нервные болезни. 2018(3):33-39. DOI: 10.24411/2226-0757-2018-12031. Изъятие (ретракция) публикации обусловлено обнаружением ошибок. Протокол заседания редакционного совета журнала «Нервные болезни» № 4 от 03.12.2019.


References
1. Olfson M, Fireman B, Weissman MM, Leon AC, Sheehan DV, Kathol RG, Hoven C, Farber L. Mental disorders and disability among patients in a primary care group practice. American Journal of Psychiatry 1997 Dec;54(12):1734-40.
2. Pshennikova MG. Stress phenomenon. Emotional stress and its role in pathology. Pathological Physiology and Experimental Therapy 2001;4:28-40 (In Russian).
3. Gold PW. The organization of the stress system and its dysregulation in depressive illness. Molecular Psychiatry 2015 Feb;20(1):32-47.
4. Mifflin K, Benson C, Kerr B, Aricioglu F, Cetin M, Dursun S, Baker G. Involvement of neuroactive steroids in pain, depression and anxiety. Modern Trends in Pharmacopsychiatry 2015;30:94-102.
5. Li CT, Lu CF, Lin HC, Huang YZ, Juan CH, Su TP, Bai YM, Chen MH, Lin WC. Cortical inhibitory and excitatory function in drug-naive generalized anxiety disorder. Brain Stimulation 2017 May-Jun;10(3):604-8.
6. Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG. Glutamate dysregulation and glutamatergic therapeutics for PTSD: evidence from human studies. Neuroscience Letters 2017 May;649:147-55.
7. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. The British Journal of Psychiatry 2001 Nov;179:390-6.
8. Tiihonen J, Kuikka J, Räsänen P, Lepola U, Koponen H, Liuska A, Lehmusvaara A, Vainio P, Könönen M, Bergström K, Yu M, Kinnunen I, Akerman K, Karhu J. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Molecular Psychiatry 1997 Oct-Nov;2(6):463-71.
9. Tiihonen J, Lepola U, Kuikka J. Benzodiazepine receptor uptake in a patient with panic disorder after citalopram treatment. Neuropsychiatry, Neuropsychology and Behavioral Neurology 1997;10:260-2.
10. Luscher B, Fuchs T. GABAergic control of depression-related brain states. Advances in Pharmacology 2015;73:97-144.
11. Shalyapina VG, Shabanov PD. Neuroendocrinology. Saint-Petersburg: Elbi-SPb; 2005. 472 p. (In Russian).
12. Marazziti D, Abelli M, Baroni S, Carpita B, Ramacciotti CE, Dell’Osso L. Neurobiological correlates of social anxiety disorder: an update. CNS Spectrums 2015 Apr;20(2):100-11.
13. Calogero AE, Gallucci WT, Gold PW, Chrousos GP. Multiple feedback regulatory loops upon rat hypothalamic corticotropin-releasing hormone secretion. Potential clinical implications. The Journal of Clinical Investigation 1988 Sep;82(3):767-74.
14. Häring M, Enk V, Aparisi Rey A, Loch S, Ruiz de Azua I, Weber T, Bartsch D, Monory K, Lutz B. Cannabinoid type-1 receptor signaling in central serotonergic neurons regulates anxiety-like behavior and sociability. Frontiers in Behavioral Neuroscience 2015 Sep;9:235.
15. Stiles J. Neural plasticity and cognitive development. Developmental Neuropsychology 2000;18(2):237-72.
16. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacology Bulletin 2001 Spring;35(2):5-49.
17. Skorzewska A, Wislowska-Stanek A, Lehner M, Turzynska D, Sobolewska A, Krzascik P, Plaznik A. Corticotropin releasing factor receptor 1 antagonist differentially inhibits freezing behavior and changes gamma-aminobutyric acidergic activity in the amygdala in low- and high-anxiety rats. Journal of Physiology and Pharmacology 2017 Feb;68(1):35-46.
18. Olexová L, Štefánik P, Kršková L. Increased anxiety-like behaviour and altered GABAergic system in the amygdala and cerebellum of VPA rats – an animal model of autism. Neuroscience Letters 2016 Aug;629:9-14.
19. Ford TC, Nibbs R, Crewther DP. Glutamate/GABA+ ratio is associated with the psychosocial domain of autistic and schizotypal traits. PLoS One 2017 Jul;12(7):e0181961.
20. Schwartz-Bloom RD, Sah R. Gamma-aminobutyric acidA neurotransmission and cerebral ischemia. Journal of Neurochemistry 2001 Apr;77(2):353-71.
21. Mumtaz F, Khan MI, Zubair M, Dehpour AR. Neurobiology and consequences of social isolation stress in animal model – a comprehensive review. Biomedicine & Pharmacotherapy 2018 Sep;105:1205-22.
22. Faye C, Mcgowan JC, Denny CA, David DJ. Neurobiological mechanisms of stress resilience and implications for the aged population. Current Neuropharmacology 2018 Mar;16(3):234-70.
23. Van Hedger K, Bershad AK, de Wit H. Pharmacological challenge studies with acute psychosocial stress. Psychoneuroendocrinology 2017 Nov;85:123-33.
24. Heizmann CW, Fritz G, Schäfer BW. S100 proteins: structure, functions and pathology. Frontiers in Bioscience 2002 May;7:d1356-68.
25. Heizmann CW. The multifunctional S100 protein family. Methods in Molecular Biology 2002;172:69-80.
26. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. The International Journal of Biochemistry & Cell Biology 2001Jul;33(7):637-68.
27. Adami C, Sorci G, Blasi E, Agneletti AL, Bistoni F, Donato R. S100B expression in and effects on microglia. Glia 2001;33:131-42.
28. Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microscopy Research and Technique 2003 Apr;60(6):614-32.
29. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, Tubaro C, Giambanco I. S100B’s double life: Intracellular regulator and extracellular signal. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research 2009 Jun;1793(6):1008-22.
30. Cupello A, Rapallino MV, Hydén H. Stimulation of 36Cl- influx into rabbit cerebral cortex microsacs by the endogenous antigen S-100. International Journal of Neuroscience 1990 Oct;54(3-4):253-8.
31. Fermin CD, Martin DS. Expression of S100 beta in sensory and secretory cells of the vertebrate inner ear. Cellular and Molecular Biology (Noisy-le-Grand, France) 1995 Mar;41(2):213-25.
32. Rebaudo R, Melani R, Balestrino M, Cupello A, Haglid K, Hydèn H. Antiserum against S-100 protein prevents long term potentiation through a cAMP-related mechanism. Neurochemical Research 2000 Apr;25(4):541-5.
33. Rajewska-Rager A, Pawlaczyk M. The role of S100B protein as a potential marker in affective disorders. Psychiatria Polska 2016;50(4):849-57.
34. Astrand R, Undén J, Romner B. Clinical use of the calcium-binding S100B protein. Methods in Molecular Biology (Clifton, N.J.) 2013;963:373-84.
35. Motin VG, Nikitin VP, Sherstnev VV. Effect of antibodies s100b protein on synaptic transmission and long-term potentiation of neurons in CA1 rat hippocampus. Bulletin of Experimental Biology and Medicine 2002;133(2):132-5 (In Russian).
36. Hydén H, Cupello A, Palm A. Effect of anti-S-100 serum on 36Cl- ion permeability across the Deiters’ neuron plasma membrane. Cellular and Molecular Neurobiology 1987 Dec;7(4):439-45.
37. Epstein OI. Release-activity: from phenomenon to new drugs. Bulletin of Experimental Biology and Medicine 2012;154(7):62-7 (In Russian).
38. Epstein OI, Shtark MB., Dygay AM, Sergeeva SA, Goldberg ED, Petrov VI, Voronina TA., Starostina MV. Pharmacology of ultra-low doses of antibodies to endogenous regulators of functions. Moscow: Russian Academy of Medical Sciences; 2005. 226 p. (In Russian).
39. Khakimova GR, Voronina TA, Dugina YuL, Ertusun IA, Epstein OI. Pharmacological effects of antibodies to S100 protein in release-active form and their implementation mechanism. SS Korsakov Journal of Neurology and Psychiatry 2016;116(4):100-13 (In Russian).
40. Bakulin IS, Tanashyan MM, Raskuragev AA. Endothelial dysfunction and oxidative stress in patients with cerebral atherosclerosis and their possible pathogenetic correction. Nervous diseases 2018;2:3-10 (In Russian).
41. Epstein OI, Vorobyova TV, Berchenko OG, Geyko VV, Garbuzova SN, Bevzyuk DD. Effect of antibodies potential form to S-100 brain-specific protein on integrative brain activity. Bulletin of Experimental Biology and Medicine 1999;127(5):547-9 (In Russian).
42. Kubista H, Donato R, Hermann A. S100 calcium binding protein affects neuronal electrical discharge activity by modulation of potassium currents. Neuroscience 1999 May;90(2):493-508.
43. Romanova GA, Voronina TA, Sergeyeva SA, Barskov IV, Dugina YuL, Epstein OI. Anti-ischemic, neuroprotective activities of proproten: a study. Siberian Herald of Psychiatry and Addiction Psychiatry 2003;1(27):123-5 (In Russian).
44. Epstein OI, Molodavkin GM, Voronina TA, Sergeeva SA. Antidepressant properties of proproten and amitriptyline: a comparative experimental study. Bulletin of Experimental Biology and Medicine 2003; 145 (Suppl 1): 34-6 (In Russian).
45. Voronina TA, Sergeeva SA, Martyushev-Poklad AV, Dugina JL, Epstein OI. Antibodies to S-100 protein in anxiety-depressive disorders in experimental and clinical conditions. In: Animal models in biological psychiatry. Kaluev AV, editor. New York, NY: Nova Science Publishers; 2006: 137-52.
46. Anti-stress action of tenotene (antibodies to S-100 brain-specific protein) depending on emotional stress reaction type: experimental and clinical studies [abstract from dissertation for the degree of Candidate of Medical Sciences]. Staraya Kupavna, Moscow region, 2006. 25 p. (In Russian).
47. Amosov ML, Saleev RA, Zarubina EV, Makarova TV. Tenoten in treatment of emotional disorders in patients with transient (cerebral) ischemic attacks (TIAs). Russian Journal of Psychiatry 2008;3:72-5 (In Russian).
48. Sharkov SB, Shirshova EV, Kuzmina VYu. Ultra-low doses of antibodies to S100 protein in treatment of autonomic disorders and anxiety in patients with organic and functional central nervous system diseases. Lechashchiy Vrach 2008;8:83-5 (In Russian).
49. Shavlovskaya OA. Tenoten in clinical practice. Effective Pharmacotherapy. Neurology and Psychiatry 2011;4:18-22 (In Russian).
50. Domashenko MA, Bolotova TA, Yershova MV, Illarioshkin SN. Efficacy and safety of tenotene as anxiolytic in patients with Parkinson’s and chronic cerebrovascular diseases. In: Proceedings of the XIV Russian National Congress “Man and Medicine”; 2007 Apr 16–20; Moscow, RF. Moscow; 2007 (In Russian).
51. Yarygina NV, Karamysheva EI, Lukutina AI. Tenoten in complex treatment of patients with multiple and combined trauma of musculoskeletal system. Effective Pharmacotherapy. Rheumatology, Traumatology, Orthopedics 2011;1:80-4 (In Russian).
52. Martin P. The epidemiology of anxiety disorders: a review. Dialogues in Clinical Neuroscience 2003 Sep;5(3):281-98.
53. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ. The economic burden of anxiety disorders in the 1990s. Journal of Clinical Psychiatry 1999 Jul;60(7):427-35.
54. Andlin-Sobocki P, Wittchen HU. Cost of anxiety disorders in Europe. European Journal of Neurology 2005 Jun;12(Suppl 1):39-44.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]